Skip to main content
Top
Published in: Dermatology and Therapy 4/2020

Open Access 01-08-2020 | Nicotinic Acid | Original Research

A Randomized Controlled Trial with a Medical Device Containing Sodium Hyaluronate and Nicotinic Acid to Increase the Efficacy of Ultraviolet Phototherapy in Psoriasis

Authors: Balázs Bende, Róbert Kui, Annamária Németh, Mariann Borsos, Zoltán Tóbiás, Gábor Erős, Lajos Kemény, Eszter Baltás

Published in: Dermatology and Therapy | Issue 4/2020

Login to get access

Abstract

Introduction

The dry and scaly skin of psoriatic patients decreases the efficacy of ultraviolet B (UVB) phototherapy. Different agents are used to facilitate the transmission of light, but most of these preparations are cosmetically unfavorable. We have tested a novel preparation containing sodium hyaluronate and nicotinic acid (UV Fotogel®; Pernix Ltd.) with the double aim to improve the efficacy of UVB phototherapy and assess the cosmetic acceptability of the preparation.

Methods

Ninety patients with plaque psoriasis were enrolled in the study, of whom 44 received narrow-band UVB (NB-UVB) phototherapy. Prior to phototherapy, one side of the patient’s body was treated with UV Fotogel while the other side served as a control. The other 46 patients used the preparation at their homes before regular sunbathing. The Local Psoriasis Severity Index (L-PSI), cosmetic acceptability and tolerability were recorded. The median values with the 25th and 75th percentiles (25p and 75p, respectively) were determined for the UV Fotogel-treated and control sites and then compared.

Results

The sides of the body to which UV Fotogel was applied prior to NB-UVB phototherapy had a significantly lower median L-PSI score than the non-treated control sides at the end of the treatment (1.0 [25p–75p: 0.0–2.0] vs. 2.0 [1.0–3.0], respectively). The application of UV Fotogel prior to sunbathing also led to a significant decrease in L-PSI score. There was a significant reduction in the median L-PSI score of patients at the final visit compared to baseline (2.5 [25p–75p: 1.5–3.5] vs. 6.0 [6.0–7.0], respectively). Use of the preparation was not accompanied by considerable adverse effects, and the patients found it cosmetically acceptable. Application of UV Fotogel prior to sunbathing was well tolerated by the patients, and the cosmetic acceptability was also good.

Conclusion

UV Fotogel is potentially a useful device for enhancement of the efficacy of phototherapy in patients with psoriasis.
Literature
1.
go back to reference Parisi R, Symmons DP, Griffiths CE, Aschroft DM. Global epidemiology of psoriasis: a systemic review of incidence and prevalence. J Invest Dermatol. 2013;133:377–85.CrossRefPubMed Parisi R, Symmons DP, Griffiths CE, Aschroft DM. Global epidemiology of psoriasis: a systemic review of incidence and prevalence. J Invest Dermatol. 2013;133:377–85.CrossRefPubMed
2.
go back to reference Kim WB, Jerome D, Yeung J. Diagnosis and management of psoriasis. Can Fam Phys. 2017;63:278–85. Kim WB, Jerome D, Yeung J. Diagnosis and management of psoriasis. Can Fam Phys. 2017;63:278–85.
3.
go back to reference Feldman SR, Fleischer AB Jr, Cooper JZ. New topical treatments change the pattern of treatment of psoriasis: dermatologists remain the primary providers of this care. Int J Dermatol. 2000;39:41–4.CrossRefPubMed Feldman SR, Fleischer AB Jr, Cooper JZ. New topical treatments change the pattern of treatment of psoriasis: dermatologists remain the primary providers of this care. Int J Dermatol. 2000;39:41–4.CrossRefPubMed
4.
go back to reference Horn EJ, Fox KM, Patel V, Chiou CF, Dann F, Lebwohl M. Are patients with psoriasis undertreated? Results of National Psoriasis Foundation survey. J Am Acad Dermatol. 2007;57:957–62.CrossRefPubMed Horn EJ, Fox KM, Patel V, Chiou CF, Dann F, Lebwohl M. Are patients with psoriasis undertreated? Results of National Psoriasis Foundation survey. J Am Acad Dermatol. 2007;57:957–62.CrossRefPubMed
5.
go back to reference Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009;60:643–59.CrossRefPubMed Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009;60:643–59.CrossRefPubMed
6.
go back to reference Ashcroft DM, Po AL, Williams HC, Griffith CE. Systematic review of comparative efficacy and tolerability of calcipotriol in treating chronic plaque psoriasis. BMJ. 2000;320:963–7.CrossRefPubMedPubMedCentral Ashcroft DM, Po AL, Williams HC, Griffith CE. Systematic review of comparative efficacy and tolerability of calcipotriol in treating chronic plaque psoriasis. BMJ. 2000;320:963–7.CrossRefPubMedPubMedCentral
7.
go back to reference Mason AR, Mason J, Cork M, Dooley G, Edwards G. Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev. 2009;(2): CD005028. Mason AR, Mason J, Cork M, Dooley G, Edwards G. Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev. 2009;(2): CD005028.
8.
go back to reference Goldenberg G, Lanoue J, Dong J. New oral therapies for psoriasis: a comprehensive review. J Clin Aesthet Dermatol. 2016;9:25–8.PubMedPubMedCentral Goldenberg G, Lanoue J, Dong J. New oral therapies for psoriasis: a comprehensive review. J Clin Aesthet Dermatol. 2016;9:25–8.PubMedPubMedCentral
9.
go back to reference Lin VW, Ringold S, Devine EB. Comparison of ustekinumab with other biological agents for the treatment of moderate to severe plaque psoriasis: a Bayesian network meta-analysis. Arch Dermatol. 2012;148:1403–10.CrossRefPubMed Lin VW, Ringold S, Devine EB. Comparison of ustekinumab with other biological agents for the treatment of moderate to severe plaque psoriasis: a Bayesian network meta-analysis. Arch Dermatol. 2012;148:1403–10.CrossRefPubMed
10.
go back to reference Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58:826–50.CrossRefPubMed Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58:826–50.CrossRefPubMed
11.
12.
go back to reference Bónis B, Kemény L, Dobozy A, Bor Z, Szabó G, Ignácz F. 308 nm UVB excimer laser for psoriasis. Lancet. 1997;350:1522.CrossRefPubMed Bónis B, Kemény L, Dobozy A, Bor Z, Szabó G, Ignácz F. 308 nm UVB excimer laser for psoriasis. Lancet. 1997;350:1522.CrossRefPubMed
13.
go back to reference Kemény L, Bónis B, Dobozy A, Bor Z, Szabó G, Ignácz F. 308-nm excimer laser therapy for psoriasis. Arch Dermatol. 2001;137:95–6.PubMed Kemény L, Bónis B, Dobozy A, Bor Z, Szabó G, Ignácz F. 308-nm excimer laser therapy for psoriasis. Arch Dermatol. 2001;137:95–6.PubMed
14.
go back to reference Novák Z, Bónis B, Baltás E, et al. Xenon chloride ultraviolet B laser is more effective in treating psoriasis and in inducing T cell apoptosis than narrow-band ultraviolet B. J Photochem Photobiol B. 2002;67:32–8.CrossRefPubMed Novák Z, Bónis B, Baltás E, et al. Xenon chloride ultraviolet B laser is more effective in treating psoriasis and in inducing T cell apoptosis than narrow-band ultraviolet B. J Photochem Photobiol B. 2002;67:32–8.CrossRefPubMed
15.
go back to reference Fetil E, Akarsu S, Ilknur T, Kusku E, Günes AT. Effects of some emollients on the transmission of ultraviolet. Photodermatol Photoimmunol Photomed. 2006;22:137–40.CrossRefPubMed Fetil E, Akarsu S, Ilknur T, Kusku E, Günes AT. Effects of some emollients on the transmission of ultraviolet. Photodermatol Photoimmunol Photomed. 2006;22:137–40.CrossRefPubMed
16.
go back to reference Otman SG, Edwards C, Pearse AD, Gambles BJ, Anstey AV. Modulation of ultraviolet (UV) transmission by emollients: relevance to narrowband UVB phototherapy and psoralen plus UVA photochemotherapy. Br J Dermatol. 2006;154:963–8.CrossRefPubMed Otman SG, Edwards C, Pearse AD, Gambles BJ, Anstey AV. Modulation of ultraviolet (UV) transmission by emollients: relevance to narrowband UVB phototherapy and psoralen plus UVA photochemotherapy. Br J Dermatol. 2006;154:963–8.CrossRefPubMed
17.
go back to reference Jain VK, Bansal A, Aggarwal K, Jain K. Enhanced response of childhood psoriasis to narrow-band UV-B phototherapy with preirradiation use of mineral oil. Pediatr Dermatol. 2008;25:559–64.CrossRefPubMed Jain VK, Bansal A, Aggarwal K, Jain K. Enhanced response of childhood psoriasis to narrow-band UV-B phototherapy with preirradiation use of mineral oil. Pediatr Dermatol. 2008;25:559–64.CrossRefPubMed
18.
go back to reference Seebode C, Lehmann J, Emmert S. Photocarcinogenesis and skin cancer prevention strategies. Anticancer Res. 2016;36:1371–8.PubMed Seebode C, Lehmann J, Emmert S. Photocarcinogenesis and skin cancer prevention strategies. Anticancer Res. 2016;36:1371–8.PubMed
19.
go back to reference Benáková N. Phototherapy of psoriasis in the era of biologics: still in. Acta Dermatovenerol Croat. 2011;19:195–205.PubMed Benáková N. Phototherapy of psoriasis in the era of biologics: still in. Acta Dermatovenerol Croat. 2011;19:195–205.PubMed
20.
go back to reference Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303:1–10.CrossRefPubMed Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303:1–10.CrossRefPubMed
21.
go back to reference Samarasekera E, Sawyer L, Parnham J, Smith CH. Assessment and management of psoriasis: summary of NICE guidance. BMJ. 2012;345:e6712.CrossRefPubMed Samarasekera E, Sawyer L, Parnham J, Smith CH. Assessment and management of psoriasis: summary of NICE guidance. BMJ. 2012;345:e6712.CrossRefPubMed
22.
go back to reference Warnecke J, Wendt A. Antiinflammatory action of pale sulfonated shale oil in UVB erythema test. Inflamm Res. 1998;47:75–8.CrossRefPubMed Warnecke J, Wendt A. Antiinflammatory action of pale sulfonated shale oil in UVB erythema test. Inflamm Res. 1998;47:75–8.CrossRefPubMed
24.
go back to reference Gambichler T. Balneophototherapy for psoriasis saltwater baths and UV-B irradiation, revisited. Arch Dermatol. 2007;143:647–9.CrossRefPubMed Gambichler T. Balneophototherapy for psoriasis saltwater baths and UV-B irradiation, revisited. Arch Dermatol. 2007;143:647–9.CrossRefPubMed
25.
go back to reference Tan SY, Buzney E, Mostaghimi A. Trends in phototherapy utilization among Medicare beneficiaries in the United States, 2000 to 2015. J Am Acad Dermatol. 2018;79:672–9.CrossRefPubMed Tan SY, Buzney E, Mostaghimi A. Trends in phototherapy utilization among Medicare beneficiaries in the United States, 2000 to 2015. J Am Acad Dermatol. 2018;79:672–9.CrossRefPubMed
26.
go back to reference Hudson-Peacock MJ, Diffey BL, Farr PM. Photoprotective action of emollients in ultraviolet therapy of psoriasis. Br J Dermatol. 1994;130:361–5.CrossRefPubMed Hudson-Peacock MJ, Diffey BL, Farr PM. Photoprotective action of emollients in ultraviolet therapy of psoriasis. Br J Dermatol. 1994;130:361–5.CrossRefPubMed
27.
go back to reference Lebwohl M, Martinez J, Weber P, DeLuca R. Effects of topical preparations on the erythemogenicity of UVB: implications for psoriasis phototherapy. J Am Acad Dermatol. 1995;32:469–71.CrossRefPubMed Lebwohl M, Martinez J, Weber P, DeLuca R. Effects of topical preparations on the erythemogenicity of UVB: implications for psoriasis phototherapy. J Am Acad Dermatol. 1995;32:469–71.CrossRefPubMed
28.
go back to reference Kemény L, Révész P, Csányi E. Composition for increasing of the effectiveness of UV-B therapy, process for the preparation thereof, and its use. Patent No.: US9839595. Alexandria: US Patent and Trademark Office. Kemény L, Révész P, Csányi E. Composition for increasing of the effectiveness of UV-B therapy, process for the preparation thereof, and its use. Patent No.: US9839595. Alexandria: US Patent and Trademark Office.
31.
go back to reference Becker LC, Bergfeld WF, Belsito DV, et al. Final report of the safety assessment of hyaluronic acid, potassium hyaluronate, and sodium hyaluronate. Int J Toxicol. 2009;28:5–67.CrossRefPubMed Becker LC, Bergfeld WF, Belsito DV, et al. Final report of the safety assessment of hyaluronic acid, potassium hyaluronate, and sodium hyaluronate. Int J Toxicol. 2009;28:5–67.CrossRefPubMed
32.
go back to reference Nilsen LT, Soyland E, Krogstad AL. Estimated ultraviolet doses to psoriasis patients during climate therapy. Photodermatol Photoimmunol Photomed. 2009;25:202–8.CrossRefPubMed Nilsen LT, Soyland E, Krogstad AL. Estimated ultraviolet doses to psoriasis patients during climate therapy. Photodermatol Photoimmunol Photomed. 2009;25:202–8.CrossRefPubMed
Metadata
Title
A Randomized Controlled Trial with a Medical Device Containing Sodium Hyaluronate and Nicotinic Acid to Increase the Efficacy of Ultraviolet Phototherapy in Psoriasis
Authors
Balázs Bende
Róbert Kui
Annamária Németh
Mariann Borsos
Zoltán Tóbiás
Gábor Erős
Lajos Kemény
Eszter Baltás
Publication date
01-08-2020
Publisher
Springer Healthcare
Published in
Dermatology and Therapy / Issue 4/2020
Print ISSN: 2193-8210
Electronic ISSN: 2190-9172
DOI
https://doi.org/10.1007/s13555-020-00385-9

Other articles of this Issue 4/2020

Dermatology and Therapy 4/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.